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Figure 3. Representation of an ovarian
cancer. Taken from: http://www.michaelwos-
nick.com/new-promise-detecting-ovarian-
cancers-earlier/
Introduction and objectives
Ovarian cancer is the 6th most frequent and the most lethal of the gynaecological cancers; it its oestrogen dependent and it is associated with 
mutations in BRCA1 and BRCA2 genes. Both oestrogens and progesterone, and BRCA1 gene have important roles in the regulation of telomerase and 
telomeres, key structures in development and in progress in every epithelial cancer. 
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Figure 6. Consequences of telomere shortening. Taken
from: Feldser, D. et al. (2003)
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Ovarian cancer is one of the most frequent and the most lethal of
gynaecological cancers, it is hormone dependent and it is associated
with mutations in BRCA1 and BRCA2 genes. It is known that
oestrogens and BRCA1 have an important paper in the regulation of
telomeres and telomerase, a structure and an enzyme that are
deregulated in almost every epithelial cancer.
Bibliography research in
PubMed and summary of all
the information collected.
Writing a memory that
relates all the items and
briefly represent them here.
There is not an effective
diagnostic, prognostic or
treatment for this disease, so,
the aim of these review is to
improve this thanks to the
knowledge of the importance,
the implication and the
regulation of telomeres and
telomerase in this cancer.
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Ovarian cancer is the most lethal of
gynaecological cancers and the 6th most
frequent. It normally does not present symptoms
and for that there is not any diagnostic. In
addition, it usually develops early metastasis,
contributing to a high mortality.
It is related to hormones: having no child, an
onset menopause or an early menstruation
favour the development of the disease.
On the contrary,
giving birth, ta-
king oral anti-
conceptives or
having tubal li-
gation prevent
the apparition of
this cancer.
10% of the ovarian cancers are hereditary:
Association with tumour suppressors that act
as Knudson model
The most important genes are BRCA1 and BRCA2,
both of them codifies proteins that repair double
strand breaks (DBSs)
•BRCA1: Associated
with a probability of
39% of causing
ovarian cancer.
•BRCA2: Associated
with a probability of
11-17% of causing
ovarian cancer
Figure 2. PubMed logo. Taken from:
http://www.ncbi.nlm.nih.gov/pubmedFigure. 1 Relationship of telomeres, telomerase,
BRCA1, hormones and ovarian cancer
Studying ovarian cancer is difficult because normally when it is
detected it has already formed metastasis, so there are not
many papers of early stages. However, some studies stablish
the importance of telomeres and telomerase in ovarian
cancer:
Figure 4. Chromosomic localization.
Modified from: Bolton KL, Chenevix- Trench
G, Goh C, et al. (2012)
• Counter, C.M. et al (1994): Studies in cells from
metastatic ovarian carcinomas. Extremely short
telomeres were maintained in tumour cells and only
telomerase was active in malignant cells, while normal
ones did not present this expression.
Figure 5. Graphic of telomeres and telomerase. Modified from: 
http://www.massgeneral.org/news/graphic_nobel.aspx
Figure 11. Structure of a LHRH antagonist (1), tamoxifen (2), and an
aramotase inhibidor (3)
Hormonal therapies consist in using hormones or
drugs that block some hormones to heal or treat
some types of cancer. In ovarian cancer there are
three, but no one of them are really effective, so they
are not normally used.
1. LHRH antagonists: Remove the oestrogen
production in the ovary.
2. Tamoxifen: It is very used in mammalian
cancer, it acts like an anti-oestrogen.
3. Aromatase inhibitors: Blocks the aromatase
enzyme, which can transform diverse
hormones into oestrogen.
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Figure 8. Role of BRCA1 in maintenance of telomeres. A shows how
BRCA1 is recruited to telomeres by RAD50, a component of MRNA. B
shows a sobreexpression of BRCA1, that causes telomeric lengthening
and an inhibition of telomerase. C shows that when BRCA1 is mutated
chromosomal aberrations are formed as a consequence of the
telomeric dysfunction. Taken from: Rosen, M. E. (2013).
BRCA1 plays an important role in the regulation of the length and the stability of telomeres
Figure 7. c-Myc induces the hTERT
promoter to express telomerase, but
when BRCA1 is expressed it inhibits its
activity. That way BRCA1 is able to
inhibit hTERT and to regulate the
length of telomeres.
It can be concluded that both telomeres and telomerasa have key roles in the development and the progress in
ovarian cancer. In the early stages of the disease it can be supposed that the telomeric dysfunction is fundamental
for the formation of tumour cells. Moreover, it can be proved that an activation of telomerase is needed for the
maintenance of telomeres that have been shortened as a consequence of multiple divisions.
In addition, it has been proved that both, oestrogens and BRCA1 gene, two factors associated with this cancer, are
important regulators of telomerase and telomeres, either directly or indirectly. The deregulation of oestrogens
levels that occurs in ovarian cancer and mutations in BRCA1 that are associated with the disease propitiate the
activation of telomerase conducing to immortalization of tumour cells.
The use of techniques that analyse the telomerase activity and the state of telomeres in women with genetic
predisposition for ovarian cancer could help to improve her diagnostic and even implant a screening in
menopausal women. Finally, further studies in hormonal regulation could help to improve the therapies and with
everything together decrease the mortality of ovarian cancer.
Different studies suggest that oestrogens and other hormones, as progesterone or androgens, could be involved
in the regulation of hTERT transcription
●Oestrogens: Studies in vitro have shown that
an increment of oestrogen expression in tumour
cells increases hTERT transcription. Specifically
oestrogens directly interact with the hTERT
promoter because it has an imperfect oestrogen
element response (ERE), it only has one
nucleotide of difference with the consensus
sequence of oestrogen receptor (ER):
GGTCAGGCTGATC / GGTCAN3TGACC
ERE Sequence ER Sequence Figure 9. Effects of oestrogen in hTERT promoter. 
●Progesterone: It has an antagonistic effect to
oestrogens. It inhibits the expression of hTERT because the
hormone upregulates p21, a kinase that inhibits the hTERT
transcription. This way progesterone indirectly regulates
hTERT expression because other studies have
demonstrated that does not exist any imperfect
progesterone element response (PRE) in hTERT promoter
Figure 10. Effects of progesterone in hTERT
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Figure. 12 Ovarian cancer ribbon. Taken from: 
http://www.ovariancancer.org
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